Zobrazeno 1 - 2
of 2
pro vyhledávání: '"Martin Henner Voss"'
Autor:
John F. Gerecitano, Shanu Modi, Raajit Rampal, Alexander E. Drilon, Matthew G. Fury, Mrinal M. Gounder, James J. Harding, David Michael Hyman, Anna M. Varghese, Martin Henner Voss, Fallon Olga France, Tony Taldone, Erica Gomes DaGama, Mohammad Uddin, Gabriela Chiosis, Jason Stuart Lewis, Serge K. Lyashchenko, Steven M. Larson, Christina Pressl, Mark Dunphy
Publikováno v:
Journal of Clinical Oncology. 33:2537-2537
2537 Background: PU-H71 (PU) is an HSP-90 inhibitor that can be labeled with 124I without altering its biochemical properties. Intratumoral drug concentration can be calculated based on 124I-PU-H71 (*PU) PET imaging, leading to a surrogate marker of
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::91eb2d478c6938f23e3b47904b5ea9b1
https://doi.org/10.1200/jco.2015.33.15_suppl.2537
https://doi.org/10.1200/jco.2015.33.15_suppl.2537
Autor:
Diogo Assed Bastos, Ana M. Molina, Xiaoyu Jia, Susanne Velasco, Sujata Patil, Martin Henner Voss, Darren Richard Feldman, Robert John Motzer
Publikováno v:
Journal of Clinical Oncology. 32:497-497
497 Background: Brain metastases (Bm) in RCC are associated with poor prognosis. The safety and efficacy of TT in this setting is not well established since patients (pts) with Bm were excluded from pivotal clinical trials. The primary objective was
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::521bae28739b74d5eb86f38439e1d324
https://doi.org/10.1200/jco.2014.32.4_suppl.497
https://doi.org/10.1200/jco.2014.32.4_suppl.497